ILMN - Illumina, Inc. Price to Earnings Adjusted for Growth Rate

The P/E growth potential metric on the GURU.Markets system summary chart demonstrates the asset's dynamics, where 2.52 records a new level. The scaling model of Illumina, Inc. (ILMN) is based on the sale of high-margin consumables for its installations. Dominating the B2B genomics segment, Illumina, Inc. (ILMN) supplies clinics and laboratories. Despite regulatory pressure regarding the Grail deal, the ecosystem remains closed to third-party reagents.

The PEG ratio is calculated by dividing the P/E ratio by the annual earnings growth rate, determining the fair value of an asset relative to its expansion. The value of 2.52 allows for an assessment of the fundamental margin of safety for Illumina, Inc. (ILMN), whose technological dominance in genome sequencing and the restoration of shareholder confidence confirm, through this growth-based undervaluation, the potential for a long-term recovery in share prices.